B
Description
Clinical-stage biopharmaceutical focused on hepatitis D and B. Lead candidate: Brelovitug (BJT-778), a human IgG1 monoclonal antibody for chronic hepatitis D with 100% virologic response in Phase 2. FDA Breakthrough Therapy designation (2025) and EMA PRIME. Acquired by Mirum Pharmaceuticals in 2026.